For example, Tim-3, a checkpoint receptor, is a promising targeted therapy in cancer immunotherapy, and its inhibitor, cobolimab, has displayed efficacy and safety as monotherapy or in combination with other checkpoint inhibitors in patients with advanced solid tumors in phase I AMBER study (Falchook GS et al., 2022), and has been also proposed in high-risk MDS (Lee P et al., 2021). The gene discussed is HAVCR2; the disease is cancer.